TRANSMEDICS GROUP INC (TMDX) Stock Price & Overview
NASDAQ:TMDX • US89377M1099
Current stock price
The current stock price of TMDX is 102.2 USD. Today TMDX is down by -2.79%. In the past month the price decreased by -24.05%. In the past year, price increased by 49.02%.
TMDX Key Statistics
- Market Cap
- 3.505B
- P/E
- 36.37
- Fwd P/E
- 39.09
- EPS (TTM)
- 2.81
- Dividend Yield
- N/A
TMDX Stock Performance
TMDX Stock Chart
TMDX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TMDX. When comparing the yearly performance of all stocks, TMDX is one of the better performing stocks in the market, outperforming 79.07% of all stocks.
TMDX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to TMDX. While TMDX has a great health rating, its profitability is only average at the moment.
TMDX Earnings
On February 24, 2026 TMDX reported an EPS of 0.53 and a revenue of 160.76M. The company beat EPS expectations (32.92% surprise) and beat revenue expectations (1.22% surprise).
TMDX Forecast & Estimates
20 analysts have analysed TMDX and the average price target is 148.92 USD. This implies a price increase of 45.71% is expected in the next year compared to the current price of 102.2.
For the next year, analysts expect an EPS growth of -6.95% and a revenue growth 23.08% for TMDX
TMDX Groups
Sector & Classification
TMDX Financial Highlights
Over the last trailing twelve months TMDX reported a non-GAAP Earnings per Share(EPS) of 2.81. The EPS increased by 178.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.43% | ||
| ROA | 17.81% | ||
| ROE | 40.22% | ||
| Debt/Equity | 1.06 |
TMDX Ownership
TMDX Latest News, Press Relases and Analysis
TMDX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 18.21 | 182.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 45.84 | 166.923B | ||
| SYK | STRYKER CORP | 22 | 125.388B | ||
| BSX | BOSTON SCIENTIFIC CORP | 20.07 | 103.546B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.25 | 48.015B | ||
| IDXX | IDEXX LABORATORIES INC | 38.67 | 45.839B | ||
| BDX | BECTON DICKINSON AND CO | 11.54 | 45.066B | ||
| RMD | RESMED INC | 18.12 | 32.969B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.84 | 32.905B | ||
| DXCM | DEXCOM INC | 26 | 25.724B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.51 | 17.147B | ||
| HOLX | HOLOGIC INC | 15.42 | 16.859B | ||
| PODD | INSULET CORP | 33.74 | 15.206B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TMDX
Company Profile
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 898 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Company Info
IPO: 2019-05-02
TRANSMEDICS GROUP INC
200 Minuteman Road
Andover MASSACHUSETTS 01810 US
CEO: Waleed H. Hassanein
Employees: 728
Phone: 19785520900
TRANSMEDICS GROUP INC / TMDX FAQ
Can you describe the business of TRANSMEDICS GROUP INC?
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 898 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Can you provide the latest stock price for TRANSMEDICS GROUP INC?
The current stock price of TMDX is 102.2 USD. The price decreased by -2.79% in the last trading session.
Does TRANSMEDICS GROUP INC pay dividends?
TMDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TMDX stock?
TMDX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is TRANSMEDICS GROUP INC (TMDX) expected to grow?
The Revenue of TRANSMEDICS GROUP INC (TMDX) is expected to grow by 23.08% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does TRANSMEDICS GROUP INC (TMDX) report earnings?
TRANSMEDICS GROUP INC (TMDX) will report earnings on 2026-05-06.
Can you provide the ownership details for TMDX stock?
You can find the ownership structure of TRANSMEDICS GROUP INC (TMDX) on the Ownership tab.